Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) has commenced a Phase 2 clinical trial of GLK-301, targeting Dry Eye Disease (DED). This investigational drug, using Glaukos' innovative iLution platform, is formulated as a cream applied to the eyelids for transdermal delivery of pilocarpine. The trial will assess safety and efficacy across 200 patients over 28 days, followed by a safety follow-up. This development addresses a significant clinical need in the ophthalmic market, as stated by CEO Thomas Burns, emphasizing the potential of the iLution platform in treating chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) has initiated the first patient enrollment in a Phase 2 clinical trial for GLK-302, targeting presbyopia treatment. This investigational drug employs the iLution platform's cream-based drug formulation for transdermal delivery via the eyelid. The trial is designed to assess safety and efficacy across three dosage levels with 120 presbyopic patients expected to participate. The company seeks to address unmet needs for effective, dropless therapies as presbyopia affects millions globally.
Glaukos Corporation (NYSE: GKOS) has received 510(k) clearance from the U.S. FDA for its iPRIME™ Viscodelivery System, which is designed for the delivery of viscoelastic fluid during ophthalmic surgery. This sterile, single-use device represents an advancement in minimally invasive glaucoma surgery (MIGS) technology. CEO Thomas Burns highlighted the importance of this clearance in expanding Glaukos' innovative ophthalmic solutions and maintaining their leadership in the MIGS marketplace.
Glaukos Corporation (NYSE: GKOS) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 5:15 p.m. ET. The event will be accessible via a live and archived webcast on Glaukos' investor relations website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent devices, launched between 2012 and 2020, and offers pharmaceuticals for corneal health enhancement.
Glaukos Corporation (NYSE: GKOS) announced the retirement of Chairman William J. Link, effective December 31, 2021, after two decades of service. Thomas W. Burns, President and CEO, will succeed him as Chairman. The board also appointed Mark J. Foley as lead independent director. The company expressed gratitude for Link's contributions and confidence in Burns' leadership for future growth and innovation in treating chronic eye diseases.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, announced its management's participation in key investor conferences. Highlights include a pre-recorded presentation at the Piper Sandler Annual Healthcare Conference available from November 22, 2021, along with one-on-one meetings on December 1, 2021. Additionally, Glaukos will feature at the Stephens Annual Investment Conference on November 29, 2021. Interested parties can access live and archived webcasts in the Investors section of the Glaukos website.
Glaukos Corporation (NYSE: GKOS) announced its participation in the American Academy of Ophthalmology (AAO) annual meeting from November 12-15, 2021, in New Orleans, Louisiana. Their technologies will be featured in various scientific programs, highlighting significant presentations on glaucoma and corneal health. Key topics include patient outcomes from different glaucoma surgeries and long-term effectiveness of corneal treatments. Glaukos will also exhibit at booth #4015, showcasing its innovations in ophthalmic medical technology.
Glaukos Corporation (GKOS) reported a 15% increase in net sales for Q3 2021, reaching $74.7 million, up from $64.8 million in Q3 2020. Key segments included glaucoma sales of $58.5 million and corneal health sales of $16.2 million. The gross margin was approximately 79%, and operating expenses totaled $48.3 million. Net income for the quarter was $6.2 million, or $0.13 per diluted share, compared to a net loss of $15.7 million in the prior year. The company anticipates full-year net sales between $285 million to $290 million.
Glaukos Corporation (NYSE: GKOS) will announce its third quarter 2021 financial results after market close on November 4, 2021. A conference call and webcast will follow at 1:30 p.m. PDT. Investors can access the live webcast via the company's website. The company specializes in innovative treatments for glaucoma, corneal disorders, and retinal diseases, including the pioneering Micro-Invasive Glaucoma Surgery (MIGS) and its iStent® devices.
Glaukos Corporation (NYSE: GKOS) announced its participation in the European Society of Cataract and Refractive Surgeons (ESCRS) Annual Meeting from October 8-11, 2021, in Amsterdam. The company will showcase its technologies through key presentations and educational symposiums on glaucoma and corneal health. Notable research includes the impact of the iStent inject in glaucoma surgeries, and customized corneal cross-linking for keratoconus. Glaukos aims to highlight its innovations in minimally invasive surgical options to improve patient care in ophthalmology.